Patent intelligence · US
US 10265282
Cancer treatment
Cancer treatment
Patent details — US 10265282
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 23, 2019
- Expiration
- Apr 18, 2039
- Applicant
- VANDA PHARMACEUTICALS INC.
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K31/165, A61K38/00
Quick answer
US 10265282 (Cancer treatment) is held by VANDA PHARMACEUTICALS INC.. Status: granted. Granted Apr 23, 2019. Expires Apr 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- VANDA PHARMACEUTICALS INC.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K31/165, A61K38/00, A61K9/0019, A61K9/0053
More from VANDA PHARMACEUTICALS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12427132
Method of improving sleep
granted -
US 12419869
Methods of treating multiple sclerosis
granted -
US 12409167
Pharmaceutical combination comprising a selective S1P1 receptor agonist
granted -
US 12403134
Method for improving or enhancing cognition
granted -
US 12357616
Methods of treating multiple sclerosis
granted -
US 12336980
Dosing regimen for a selective S1P1 receptor agonist
granted -
US 12318375
Method of treatment with tradipitant
granted -
US 12201604
Treatment of circadian rhythm disorders
granted
Frequently asked questions
What is US patent 10265282?
US 10265282 (Cancer treatment) is held by VANDA PHARMACEUTICALS INC.. Status: granted. Granted Apr 23, 2019. Expires Apr 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10265282?
VANDA PHARMACEUTICALS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 96 pharmaceutical patents for this assignee.
When does US 10265282 expire?
Our index shows an expiration date of Apr 18, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.